Lexeo Therapeutics closed at $3.23 on Nov 4, up 3.86%, 69.6% below its 52-week closing high. Volume of 1.2M shares was 0.85× its 20-day average (close to normal).
Split-adjusted performance: -2.1% over one month, -48.2% over six months, -64.3% over one year.
Short interest was 17.6M shares at the Oct 15 settlement, down 8.8% from the prior report (22.9% of float, 10.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LXEOLexeo Therapeutics | $3.23 | +3.86% | −48.2% | — | — | — | $265.1M | |
| LCTXLineage Cell Therapeutics | $1.03 | +1.98% | −28.0% | −61.3% | 138.6% | — | $260.5M | Compare |
| ALECAlector | $2.28 | +11.22% | −11.3% | −57.8% | −692.5% | — | $254.6M | Compare |
| FATEFate Therapeutics | $2.09 | +2.45% | −8.7% | +9.2% | −1448.6% | — | $250.4M | Compare |
| SABSSAB Biotherapeutics | $3.18 | +1.92% | −16.3% | — | — | — | $289.3M | Compare |
| CABACabaletta Bio | $1.42 | 0.00% | −61.9% | — | — | — | $240.8M | Compare |
| OCGNOcugen | $0.8745 | +17.35% | −39.9% | +8.4% | −1671.8% | — | $296.6M | Compare |
| PROKProKidney | $1.12 | +4.67% | −42.9% | −32.1% | −18948.0% | — | $234.1M | Compare |
| IPSCCentury Therapeutics | $1.67 | +9.87% | −28.6% | — | — | — | $302.4M | Compare |
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
